Source: ERJ Open Res, 5 (1) 00185-2018; 10.1183/23120541.00185-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Lowie E.G.W. Vanfleteren, Anders Ullman, Anita Nordenson, Anders Andersson, Kristina Andelid, Leonardo M. Fabbri. Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box. ERJ Open Res, 5 (1) 00185-2018; 10.1183/23120541.00185-2018

Member's Comments

No comment yet.

Related content which might interest you: Triple therapy in COPD: Oportunities and challenges Source: Short Video Statement 2020 Year: 2020 Triple therapy in COPD: only for the right patient Source: Eur Respir J, 53 (4) 1900394; 10.1183/13993003.00394-2019 Year: 2019 LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Patient selection? One fits all (monotherapy versus combined therapy)? Source: Sleep and Breathing Conference 2021 Year: 2021 Treatment of idiopathic pulmonary fibrosis (IPF) with nintedanib: an experience from the compassionate use program (CUP) in Estonia Source: International Congress 2017 – Clinical problems in lung diseases Year: 2017 Is pulmonary rehabilitation (PR) an effective therapy in lymphangioleiomyomatosis (LAM)? Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012 The importance of the aplication long-therm therapy (LTOT) in COPD tretmant Source: Eur Respir J 2006; 28: Suppl. 50, 519s Year: 2006 Triple therapy trials in COPD: a precision medicine opportunity Source: Eur Respir J, 52 (6) 1801848; 10.1183/13993003.01848-2018 Year: 2018 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015 Tobacco smoking (TS) in home oxygen therapy (HOT). Preliminary data (*) Source: Annual Congress 2013 –COPD and tobacco management Year: 2013 Bronchodilator combinations for COPD: real hopes or a new Pandora’s box? Source: Eur Respir J 2013; 42: 1441-1445 Year: 2013 Is occupational therapy (OT) really needed in pulmonary rehabilitation programmes (PRP)? Source: Eur Respir J 2005; 26: Suppl. 49, 529s Year: 2005 LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results) Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 Exacerbation frequency and eosinophil levels for GOLD C and D COPD patients currently prescribed multiple inhaler triple therapy (MITT) Source: International Congress 2018 – Epidemiology of asthma, COPD and factors that associate with lung function Year: 2018 Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 A randomised controlled trial of cognitive behavioural therapy (CBT) delivered by respiratory nurses to reduce anxiety in chronic obstructive pulmonary disease (COPD). (Trial registration - ISCRCTN55206395) Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016